{rfName}
Ev

Indexed in

License and Use

Icono OpenAccess

Citations

7

Altmetrics

Analysis of institutional authors

Iftimie, SimonaAuthorJoven, JorgeAuthorCastro, AntoniAuthor

Share

February 10, 2025
Publications
>
Article
Sí

Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain

Publicated to: Bmc Infectious Diseases. 25 (1): 117- - 2025-01-24 25(1), DOI: 10.1186/s12879-025-10524-2

Authors:

Iftimie, S; Ladero-Palacio, P; López-Azcona, AF; Pujol-Galarza, L; Pont-Salvadó, A; Gabaldó-Barrios, X; Joven, J; Camps, J; Castro, A; Pascual-Queralt, M
[+]

Affiliations

Univ Rovira i Virgili, Hosp Univ St Joan, Inst Invest Sanit Pere Virgili, Dept Clin Lab, Reus, Spain - Author
Univ Rovira i Virgili, Hosp Univ St Joan, Inst Invest Sanit Pere Virgili, Dept Internal Med,Res Grp Autoimmun Infect & Throm, Reus, Spain - Author
Univ Rovira i Virgili, Hosp Univ St Joan, Inst Invest Sanit Pere Virgili, Dept Urol, Reus, Spain - Author
Univ Rovira i Virgili, Hosp Univ St Joan, Inst Invest Sanit Pere Virgili, Unitat Recerca Biomed, Reus, Spain - Author
See more

Abstract

Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune (R), a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens. Methods This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus from January 2018 to August 2022, assessed the association between Uromune (R) administration and changes in recurrent UTIs. Patients received personalized autovaccines administered as two sublingual puffs daily for three months. Clinical, microbiological, and demographic data were analyzed to assess treatment outcomes and identify recurrence-associated factors. Results Forty-nine patients (mean age, 61 years, and 59.2% women) were included in the study. Uromune (R) treatment decreased UTI episodes from 3.73 +/- 0.97 the year before to 0.98 +/- 1.36 (p < 0.001) the year after its administration. The number of patients who suffered three or more episodes per year dropped from 43 (87.7%) before the intervention to 7 (14.3%) afterwards. The maximum effectiveness of the autovaccine was observed three months post-administration, with 44 patients not experiencing any UTI episodes. Regression analysis identified having had a urostomy, chronic kidney disease, and being immunosuppressed as predictors of recurrence. Conclusion Uromune (R) autovaccine was associated with a significant reduction in the frequency of recurrent UTIs and related hospitalizations, offering substantial relief to patients. These findings suggest that Uromune (R) may be a promising option for managing recurrent UTIs, though controlled studies are needed to confirm its efficacy compared to standard treatments.
[+]

Keywords

AdultAgedAntibiotic resistanceBacterial vaccineBacterial vaccinesFemaleHumansImmunotherapyMaleMiddle agedPilot projectsPreventionRecurrenceRecurrent urinary tract infectionsRetrospective studiesSpainSublingual bacterial vaccineTreatment outcomeUrinary tract infectionsUromune (r) vaccinUromune® vaccineWome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal BMC INFECTIOUS DISEASES due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Infectious Diseases.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-05:

  • WoS: 2
  • Scopus: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 22.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 21 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 13.
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: http://hdl.handle.net/20.500.11797/imarina9438497
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Iftimie Iftimie, Simona Mihaela) and Last Author (Pascual-Queralt, Merce).

the author responsible for correspondence tasks has been Camps, Jordi.

[+]